cagrilintide vs retatrutide vs tirzepatide vs. Tirzepatide: The New Contender vs. the Current Leader Retatrutide vs Tirzepatide: Mechanism, Trial
Description
Type 2 diabetes patients experienced HbA1c declines of up to 2.0% with retatrutide
Gastrointestinal adverse events, primarily nausea, vomiting, diarrhea, and constipation, are the predominant side effects, occurring most frequently during dose escalation and generally diminishing with continued treatment
When nutrient consumption drops, the body may struggle to maintain optimal energy production and circulation
These plateaus are normal and do not necessarily indicate that your dose is inadequate
2020;105(8):e27102716
Create figures that effectively communicate your research in half the time using our editable icons
